Klaus Edvardsen has been named chief medical officer (CMO) of Epitopea, an Anglo-Canadian company developing off-the-shelf RNA-based immunotherapies.

Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, ...

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today ...

Protein synthesis is vital for life, translating genetic information from DNA to functional proteins through transcription ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

UMD researchers have discovered key mechanisms in gene regulation that could improve the design of RNA-based medicines.

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

RedHill Biopharma Ltd (RDHL) reported its Q1 2022 earnings, revealing a decrease in net revenues to $18.2 million from $22.1 million in the previous quarter. Despite this, the company achieved a gross ...